Efficacy of high-dose aripiprazole for treatment-resistant schizoaffective disorder: a case report.
Aripiprazole is an atypical neuroleptic with a unique mechanism of action. According to the package insert, the maximum recommended dose for aripiprazole is 30 mg/day. In clinical practice, off-label prescribing of medications, including the use of doses that exceed the manufacturer's recommendations, is not uncommon. Most premarketing studies are designed principally to demonstrate safety, efficacy, and tolerability and often exclude many patients who are treated after a drug has been released.To report a case with treatment-resistant schizoaffective disorder in which a patient tolerated and responded to high-dose aripiprazole; an objective is to discuss the use of aripiprazole dosages at higher than those recommended in the product's labelling.
Bakirkoy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, Istanbul, Turkey. osaatcioglu@superonline.com
Omer
O
Saatcioglu
Sevda
S
Gumus
Kirkor
K
Kamberyan
Medaim
M
Yanik
D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage*; D000068180:Aripiprazole; D004348:Drug Labeling; D004351:Drug Resistance; D005260:Female; D006801:Humans; D056687:Off-Label Use; D010879:Piperazines / Q000008:administration & dosage*; D011618:Psychotic Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D015363:Quinolones / Q000008:administration & dosage*; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D000068180:Aripiprazole